The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
April 4th 2024
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes
June 5th 2016Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.
Dr. Levy on Impact of Nivolumab, Pembrolizumab Approvals in NSCLC
April 12th 2016Benjamin P. Levy, MD, assistant professor of Medicine, Hematology, and Medical Oncology at Mount Sinai Hospital, discusses how nivolumab (Opdivo) and pembrolizumab (Keytruda) have impacted the treatment landscape of non–small cell lung cancer.
Expert on PD-L1/CTLA-4 Blockade and Future of Immunotherapy in Lung Cancer
March 17th 2016Scott J. Antonia, MD, discusses how the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic non–small cell lung cancer, irrespective of PD-L1 status.
Dr. Martins on Patient Selection for Nivolumab in NSCLC
February 15th 2016Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).
Dr. Ramalingam on Emerging Combination Regimens in NSCLC
Suresh Ramalingam, MD, professor, Emory School of Medicine, and chief, Medical Oncology, Department of Hematology and Medical Oncology, Emory University, discusses combinations with immunotherapy agents and chemotherapy being investigated as potential treatments for patients with non–small cell lung cancer.
Vaccine Strategy for Biomarker in NSCLC Reaches Phase III Study
January 27th 2016An emerging vaccine strategy, of TG4010 immunotherapy and first-line chemotherapy, that could target a potential new biomarker in patients with advanced non-small cell lung cancer (NSCLC) has successfully reached a phase III clinical trial, researchers noted.
Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLC
January 7th 2016Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).
Durvalumab/Tremelimumab Combo Shows Promise in NSCLC, Regardless of PD-L1 Status
December 1st 2015Naiyer A. Rizvi, MD, discusses results of a study looking at the combination of the anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) with the anti–CTLA-4 monoclonal antibody tremelimumab in patients with advanced non–small cell lung cancer.
Dr. Garon on Incorporating Immunotherapies Into Lung Cancer Treatment
November 30th 2015dward Garon, MD, assistant professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles, discusses incorporating immunotherapies into the treatment of patients with lung cancer.